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In recent years, a number of new developments in targeted therapies using radiolabeled compounds
have emerged. New developments and insights in radioiodine treatment of thyroid cancer, treatment of
lymphoma and solid tumors with radiolabeled monoclonal antibodies (mAbs), the developments in the
application of radiolabeled small receptor-specific molecules such as meta-iodobenzylguanidine and
peptides and the position of locoregional treatment in malignant involvement of the liver are reviewed. The
introduction of recombinant human thyroid-stimulating hormone and the possibility to enhance iodine uptake
with retinoids has changed the radioiodine treatment protocol of patients with thyroid cancer. Introduction of
radiolabeled mAbs has provided additional treatment options in patients with malignant lymphoma, while
a similar approach proves to be cumbersome in patients with solid tumors. With radiolabeled small molecules
that target specific receptors on tumor cells, high radiation doses can be directed to tumors in patients
with disseminated disease. Radiolabeled somatostatin derivatives for the treatment of neuroendocrine tumors
are the role model for this approach. Locoregional treatment with radiopharmaceuticals of patients with
hepatocellular carcinoma or metastases to the liver may be used in inoperable cases, but may also be
of benefit in a neo-adjuvant or adjuvant setting. Significant developments in the application of targeted
radionuclide therapy have taken place. New treatment modalities have been introduced in the clinic. The concept
of combining therapeutic radiopharmaceuticals with other treatment modalities is more extensively explored.
Key words: peptide receptor radionuclide therapy, radioimmunotherapy, radionuclide therapy, radioiodine therapy,
radiopharmaceuticals, transarterial radionuclide therapy
introduction
In recent years, a number of new developments in targeted
therapies using radiolabeled compounds have emerged. These
vary from new insights in the treatment of thyroid cancer with
radioiodine to the application of radiolabeled monoclonal
antibodies (mAbs) and designer peptides. In this review, the
current status and new developments in targeted radionuclide
therapy are addressed.
new developments in radioiodine
treatment of thyroid cancer
Radioiodine has been applied in millions of patients with
benign and malignant thyroid diseases for >50 years. When
administered systemically, I-131 is concentrated in thyroid
tissue, achieving high intrathyroidal radiation doses thereby
generating a therapeutic effect due to the emission of charged
particles (electrons, b radiation). Due to the limited range,
the cervical soft tissues are spared. I-131 accumulates in
a given follicle, irradiates integral cellular structures such as
cytoplasm and nucleus and may also irradiate neighboring
cells and follicles. The aim of postoperative radioiodine therapy
in differentiated thyroid cancer (DTC) is the selective
irradiation of iodine-avid thyroid remnants and thyroid
carcinoma [1–3].
Although DTC is relatively resistant to radiation, radioiodine
treatment is an effective method due to the potentially high
local dose that can be achieved [4]. Papillary and follicular
tumors generally express the sodium iodide symporter (NIS),
which is the key cellular feature for specific uptake of
radioactive iodine [5, 6].
The target dose to the tissue is the determinant for successful
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activities in the range of 1.1–3.7 GBq (30–100 mCi) of
radioiodine [7]. An alternative approach is based on
pretherapeutic individual dosimetry [8]. Dosing concepts were
established based on quantitative dosimetry to estimate the
activity needed to deliver an effective radiation dose (e.g. 300
Gy). This requires several measurements of the uptake of
a tracer activity of radioiodine. Nevertheless, tumor doses
exceeding 500 Gy can be achieved by systemic application of
I-131, while external irradiation usually leads to <70 Gy [9].
Especially in high-risk patients, extending I-131 therapy to its
limits may be beneficial. The indication for repeated high-dose
treatments should be considered after individualized risk
stratification [10]. The effect of radioiodine treatment
correlates inversely with tumor mass and extent. Younger age
is predictive of favorable response. Figure 1 shows an example
of successful treatment of diffuse pulmonary metastases by
repetitive I-131 infusions.
Long-term adverse effects of I-131 therapy include salivary
gland dysfunction, (transient) bone marrow depression and
possibly hypofertility. There may be an elevated risk of
leukemia and other secondary malignancies, but this has not
been consistently demonstrated by follow-up studies and is
therefore likely to be very small and dependent on other
coexisting factors.
Elevated serum levels of thyroid-stimulating hormone (TSH)
are a prerequisite for a selective uptake of radioiodine in both
normal and cancerous thyroid-derived cells. Until recently,
patients were treated with I-131 in a hypothyroid state after
withdrawal of thyroid hormone therapy. Recently,
administration of recombinant human TSH (rhTSH) without
discontinuation of levothyroxine intake has been shown to be
as effective for thyroid remnant ablation as conventional
approaches on the basis of the discontinuation of the TSH-
suppressive therapy with levothyroxine [11]. rhTSH has also
been used in the treatment of distant metastases. However, no
prospective, randomized studies have been conducted to date,
and the published experience only reports individual cases or
case series [12]. The main indications for rhTSH use in
metastatic disease were insufficient endogenous TSH
production, serious concomitant illnesses or high patient age
and generally poor condition. In general, it is believed that
a considerable proportion of patients derived some clinical
benefit from rhTSH-aided radioiodine treatment, success rates
being in the range of 30%–60% including partial remissions
and stabilization of the disease [12]. The future role of
rhTSH-aided radioiodine treatment of DTC, especially in the
curative treatment, such as those with diffuse, miliary lung
metastases, needs to be elucidated in further studies.
Up to one-third of metastasized or recurrent thyroid
carcinomas may dedifferentiate over time, characterized by
a loss of growth-regulating mechanisms mediated by TSH
and/or a decline in iodine avidity making them eventually
inaccessible to radioiodine therapy [13, 14]. This effect is
commonly attributed to a lost or reduced expression of the
thyroidal sodium/iodide symporter (NIS). Since a restoration
of this essential biological feature would lead to a potential
treatment options, various groups have investigated
redifferentiating agents such as retinoid acid and its
derivatives. In vitro and in vivo studies showed that retinoids
may inhibit proliferation of malignant cells. Retinoids bind to
specific DNA sequences and modulate the transcription of
retinoic acid responsive genes. Although retinoids showed
a number of effects in vitro, they have so far failed to translate
into a marked clinical effect. Response rates in the order of
20%–30% can be expected [13, 14]. Controlled clinical trials
are warranted to establish better criteria for the pretherapeutic
selection of patients. A more sophisticated approach may be on




Chemotherapy in combination with the anti-CD20 antibody
rituximab is considered standard treatment of diffuse large
B-cell lymphoma, as well as for follicular lymphoma [16].
Most patients with disseminated B-cell lymphoma are,
however, not cured. The need for improvements in the
treatment of B-cell lymphoma and the radiosensitivity of
the disease provides the rationale for application of systemic
radiotherapy in this disease.
Two radiolabeled anti-CD20 antibodies are currently
available for radioimmunotherapy (RIT), i.e. Y-90-
ibritumomab tiuxetan (Zevalin, IDEC Pharmaceuticals and
Schering AG, Berlin, Germany) and I-131-tositumomab
(Bexxar, Glaxo Smith Kline, Philadelphia PA) [17, 18]. Both
radiolabeled mAbs are more efficacious at inducing remissions
Figure 1. Successful treatment of pulmonary metastases of pT4N1M1
papillary thyroid carcinoma by repetitive high-dose I-131 infusions.
(A). I-131 scintigraphy before treatment: diffuse pulmonary uptake of
I-131 due to diffuse lung metastases. (B) I-131 scintigraphy after two
administrations of I-131: decrease of the pulmonary uptake indicating
response of the lung metastases. (C) I-131 scintigraphy after three
administrations of I-131: no abnormal pulmonary uptake indicating
complete response.
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compared with the respective unlabeled antibody, including
rituximab [19] and also more effective than prior courses of
chemotherapy in these patients [17]. A single course of I-131-
tositumomab as initial therapy can induce 75% complete
remissions (CR) in patients with advanced follicular lymphoma
[20]. The authors found that 81% of the patients who had both
a CR and molecular response with regard to the BCL2 gene,
had a progression-free survival of 5 years, suggesting that this
very favorable subset of patients (i.e. initial therapy of follicular
B-cell lymphoma) may not benefit from additional or more
intensive treatment.
Attempts to optimize the efficacy of RIT of B-cell
lymphoma are ongoing for refractory/relapsed indolent and
aggressive B-cell lymphomas. Three factors need to be
considered: (i) choice of antibody/antigen, (ii) choice of
radionuclide, (iii) choice of delivery system/schedule.
(i) The choice of the antibody/antigen: The vast majority of
patients whose disease becomes refractory to rituximab still
have lymphoma cells that express CD20 antigen, so they remain
appropriate targets for anti-CD20-radiolabeled antibodies.
Patients with unequivocal expression of the target antigen
are reported to show a better response rate than those with
a weak expression [21]. Quantitative flow cytometry analysis of
the target antigen CD22 has shown to be a useful predictor
of the outcome of therapy with epratuzumab, a Y-90-labeled
humanized anti-CD22 immunoglobulin G antibody [21]. As
the combination of epratuzumab (anti-CD22) with rituximab
(anti-CD20) has shown to be well tolerated and having
a significant clinical activity in aggressive and indolent B-cell
lymphoma [22], a further development to explore could be
the combination of different radiolabeled antibodies labeled.
(ii) The choice of the radionuclide: Beta-emitting
radionuclides (i.e. Y-90, I-131, Cu-67, Lu-177) are mostly used
for B-cell lymphomas in clinical trials. For the treatment of
microscopic disease and leukemia, these radionuclides do have
the disadvantage that their beta energy results in energy
deposition beyond the targeted cell. Another option is the use
of targeted alpha particles with radionuclides such as bismuth-
213 or actinium-225, which offers both the possibility of
selective tumor cell kill with less damage to surrounding
normal cells and a higher radiobiological effectiveness [23, 24].
(iii) Choice of the delivery system/schedule: RIT is limited by
the absorbed dose to radiosensitive organs (bone marrow, lung,
liver and kidney). The bone marrow is the first dose-limiting
organ but myeloablation can be circumvented by stem-cell
support. To avoid toxicity of the other radiosensitive organs,
other strategies must be used as pretargeting (discussed below)
or affinity adsorption procedures [25].
In 2000, the long-term follow-up of a phase I–II high-dose
myeloablative RIT of 29 patients with B-cell lymphoma was
reported [26]. Following the phase I study, patients were
treated to a calculated maximal tolerated dose of 25–27 Gy to
normal organs to avoid cardiopulmonary toxicity,
corresponding to 12 765–29 600 MBq of I-131-tositumomab.
Approximately 85% of the patients showed objective responses
with 79% CR. After a median follow-up of 42 months, 14 were
free of progression. The overall and progression-free survival
rates were 68% and 42%, respectively. When the
pharmacokinetics of the chimeric I-131-labeled rituximab was
studied, the kidneys were almost exclusively dose limiting [27].
These differences may be due to the significant difference in
half-life between the two antibodies, the chimeric and the
murine antibodies having plasma half-lives of 88 h and 56 h,
respectively. Studies of myeloablative RIT using Y-90-labeled
antibodies are ongoing and encouraging results have been
reported [28].
A very interesting approach is the application of pretargeted
RIT to increase the therapeutic window of RIT. The
administration of the nonradioactive antitumor antibody is
separated in time from the injection of small, radioactive
molecules that can bind to the antibody. Thus, the tumor is
targeted by the mAb, which is allowed to clear from circulation
and normal organs. The small radioactive molecules which
have affinity to bind to the pretargeted antibody have the
advantage that they clear very fast from organs and tissues
where no antibody is present, thereby reducing radiation-
induced toxicity of normal organs, especially the bone marrow.
Thus, these strategies provide increased tumor-to-background
ratios and the delivery of a higher therapeutic dose. There are
two reports on successful treatments of patients with B-cell
lymphoma, using different pretargeting strategies [29, 30].
solid tumors
So far the application of radiolabeled antibodies for the
treatment of patients with solid tumors has been less successful
than in patients with malignant lymphoma. Several reasons
can be identified. First, the generally lower radiosensitivity of
solid cancers. Furthermore, solid tumors are targeted less
efficiently with radiolabeled antibodies than lymphoma due to
limited vascularization, elevated interstitial pressure and
heterogeneous uptake of the radiolabeled antibody [31]. Due to
the combination of these factors, treatment with radiolabeled
antibodies results in tumor-absorbed radiation doses that
typically do not exceed 15 Gy at dose levels when grade III/IV
hematological toxicity is observed. As large tumor size further
diminishes tumor uptake of radiolabeled antibodies, minimal
residual disease is considered the most favorable condition
for treatment with radiolabeled antibodies.
As most patients are studied in phase I/II clinical trials,
most data are derived from heavily pretreated patients, mainly
with bulky disease. Deriving efficacy data from dose-escalation
studies will never yield data on the potential efficacy at the
optimal dose in the patient population best suited for this type
of treatment.
In colorectal carcinoma (CRC), the most commonly targeted
antigen is carcinoembryonic antigen (CEA), as 95% of CRC
express this antigen. The largest series of patients who were
treated with I-131-labeled murine anti-CEA mAb NP-4
evaluated the antitumor activity of escalating activity doses of
I-131-labeled NP-4 in 57 patients with CEA-expressing
malignancies, of whom 29 had CRC [32]. Antitumor effects
were reported in 12 of 35 patients, including one partial
remission, four mixed/minor responses and seven stabilizations
of previously progressive disease. Unfortunately, the tumor
types of the responding patients were not specified. Because of
the immunogenicity of the murine form (development of
human anti-mouse antibodies), the antibody was humanized.
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In patients with small-volume liver involvement, maximum
tolerated dose (MTD) due to grade 4 hematological toxicity
after administration of I-131-labeled hMN14 proved to be
higher than in patients with bulky disease [33–35]. Seven of
nine patients in whom RIT at MTD was administered in an
adjuvant setting after resection of liver metastases did not show
evidence of recurrence at a median follow-up of 27 months
[34]. These favorable results were confirmed in a larger series of
23 patients, in whom a 5-year survival of 51% was reported,
being an improvement as compared with historical and
contemporaneous controls [36]. Still, these results need to be
addressed cautiously as the patient groups are small and the
studies lack appropriate controls. Wong et al. [37] evaluated
the Y-90-labeled, high-affinity chimeric anti-CEA mAb cT84.66
in patients with CRC. In the study, combining Y-90-cT84.66
and 5-fluorouracil (5-FU), they did not observe responses,
but did see stable disease (SD) (less than a 50% reduction and
less than a 25% increase in the sum of the products of two
perpendicular diameters of all measured lesions and the
appearance of no new lesions according to the WHO standard
criteria) in patients with previously progressive disease.
Ovarian cancer has been targeted in RIT trials using mainly
antibodies directed against the mucin-1 (MUC-1) antigen and
a few other tumor-associated glycoproteins, such as TAG-72
and gp-38 [38]. As ovarian cancer tends to stay confined to the
peritoneal cavity during the course of the disease, radiolabeled
antibodies have been administered intraperitoneally in many
trials. Nevertheless, whether or not the intraperitoneal route of
administration has significant advantages as compared with
intravenous injection is not unequivocally proven. Based on
a study by Nicholson et al. [39] who reported significantly
better median survival than a matched historical control group
and long-term survival (>10 years) after treatment with Y-90-
labeled HMFG-1 mAb, a multicenter phase III randomized
controlled trial was initiated, comparing the Y-90-HMFG-1
to best supportive care in 447 patients with ovarian cancer with
no evidence of disease following cytoreductive surgery and
platinum- or taxol-based chemotherapy, as confirmed by
diagnostic laparoscopy. Unfortunately, no significant survival
benefit was observed [40]. However, some suboptimal
choices were made. First, the antibody dose was relatively high,
which may have resulted in antigen saturation. Secondly, Y-90
is not the radionuclide of choice in minimal residual disease
due to its high beta energy that results in energy deposition
largely outside of the small tumor deposits.
Given the prevalence of breast cancer, the availability of
several mAbs and its radiosensitivity, many mostly small
clinical RIT trials have been conducted in patients with
breast cancer with a variety of radiolabeled mAbs, as recently
reviewed by DeNardo [41]. Although objective responses were
reported, patient numbers are generally too small for more
conclusive assessment.
In renal cell cancer, the antigen Carbonic Anhydrase IX is
uniformly expressed in the vast majority of cases, which are
mainly of the clear cell type. This antigen is very efficiently
targeted by the mAb G250. Several clinical trials have been
performed. In a phase I/II trial addressing the feasibility and
efficacy of repeated high-dose I-131-labeled cG250 [42],
no objective responses were recorded. However, four out of
15 assessable patients who received two therapy courses
experienced stabilization of previously progressive disease for
up to 6 months. When fractionating RIT instead of
administrating the MTD, again SD was reported in 50% of
assessable patients for 2–11 months [43]. Nevertheless,
hematological toxicity was again dose limiting and no evidence
of bone marrow sparing by fractionation was observed.
Most of the work using pretargeting strategies has been
applied in solid tumors. Recently, the methodology using the
(strept)avidin-biotin system or bispecific antibodies has been
extensively reviewed [44, 45]. Very recently, a survival benefit
has been reported in patients with medullary thyroid cancer
treated with a bispecific antibody and a small radioiodinated
peptide [46]. Furthermore, this approach is highly amendable
to further biotechnological improvements, e.g. by creating
trivalent antibodies that can target tumors more effectively [47].
radiolabeled MIBG
Uptake of meta-iodobenzylguanidine (mIBG), an
arylalkylguanidine norepinephrine analogue, by the various
organ systems reflects rich adrenergic innervation and/or
catecholamine excretion [48–50]. Thus, radiolabeled mIBG
enabled successful imaging of neuroectodermally derived
tumors (neuroblastomas, pheochromocytomas,
paragangliomas, medullary thyroid carcinomas, carcinoid
tumors, Merkel cell tumors of the skin) [51, 52].
The high sensitivity and specificity of mIBG for the detection
of primary and secondary tumor sites led to the development of
I-131 mIBG treatment of neuroectodermally derived tumors
[53, 54].
Neuroblastoma is a high-grade malignancy of childhood,
chemo- and radiosensitive but prone to relapse after initial
remission induction. Stage 1 and 2 tumors are usually cured by
surgery alone. Many stage 3 tumors are rendered operable by
neo-adjuvant chemotherapy. Sixty percent of neuroblastomas
in young children are stage 4 (undifferentiated and widely
disseminated at diagnosis). Many of these have biological
markers for poor prognosis, such as MYCN amplification or 1p
deletion [55, 56]. I-131 mIBG therapy has been used since the
80s as a palliative agent in relapsed patients [57, 58]. Figure 2
shows an example of a patient with metastatic neuroblastoma
who was in remission after two cycles of I-131 mIBG. Later, the
radiopharmaceutical was proposed in first-line therapy, as
single agent or in combination with chemotherapy [59–61], in
combination with myeloablative therapy before bone marrow
rescue [62, 63], or in consolidation therapy after induction
of a good partial remission [64–68]. In second-line therapy
after failed induction chemotherapy, I-131 mIBG can be
combined with topotecan, a radiosensitizer and stem-cell
rescue [69, 70].
In I-131 mIBG therapy, again the bone marrow is the dose-
limiting organ [64, 71]. To optimize mIBG therapy, a toxicity–
dose relationship for bone marrow suppression has been
demonstrated [72]. Thus, pretherapy dosimetry can be used to
predict the individual degree of bone marrow toxicity. In
patients with neuroblastoma who had received prior intensive
chemotherapy, dose-limiting toxicity (DLT) of a single fraction
of I-131 mIBG was myelotoxicity at 2.5 Gy whole-body dose.
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A total of 4.0 Gy whole-body dose with stem-cell rescue is
well tolerated with no other short-term organ DLT [73].
Currently, two major lines for further development of I-131
mIBG treatment are ongoing. Both involve I-131 mIBG dose
escalation to further increase the tumor radiation dose. One
approach is administration of high activity of I-131 mIBG with
stem-cell support. The activity dose was established in toxicity–
dose relationship phase I studies [71]. Whole-body (and
tumor) doses were calculated after therapy and the dose of
a second treatment is on the basis of the correlation of the
radiation dose and observed toxicity [72]. Howard et al. [68]
reported the feasibility of repetitive I-131 mIBG and achieved
a 39% overall disease response in 24 heavily pretreated patients.
The European ESIOP I-131 mIBG protocol includes patients
with high-risk neuroblastoma who failed to achieve an
adequate partial remission after induction chemotherapy.
High doses of I-131 mIBG, combined with topotecan are
administered [70] to deliver a total combined whole-body
dose of 4.0 Gy in two fractions. A stem-cell rescue is required
after the second fraction. Relatively simple dosimetry is
performed after the first fraction, calculating the activity to
be administered in the second fraction. This allows a very
homogeneous total activity dose to the patients and better
assessment of the relevant parameters, i.e. whole-body and
tumor doses. The feasibility of this protocol was recently tested
in a phase I study in eight children [69].
Phaeochromocytoma is a rare disease arising from the
adrenal gland, mainly occurring in adults [74]. It is usually
benign, but early recognition of malignant
phaeochromocytoma is critical to avoid significant morbidity
and mortality. In a small study, I-131 mIBG therapy was
evaluated in 12 patients with malignant phaeochromocytoma
[75]. Three patients were in CR and alive without evidence of
disease after a mean follow-up of 45 months. Seven patients
were in partial remission (two subsequently died of disease),
two had progressive disease (both died of disease). Grade 3
thrombocytopenia was observed after 79% of cases and
grade 3 and 4 granulocytopenia in 53% and 19% of cases. All
patients had stem cells harvested before therapy, but only one
required stem-cell return.
peptide receptor radionuclide therapy
Neuroendocrine tumors, which include pancreatic islet cell
tumors, nonfunctioning neuroendocrine pancreatic tumors
and carcinoids, are usually slow growing. The overexpression of
somatostatin receptors enables treatment of tumor
hypersecretion and of primary and metastatic lesion growth
due to postreceptor signaling, triggered by the receptor–ligand
internalization [76–79]. Treatment with somatostatin
analogues yields symptomatic and biochemical responses in
73% and 77% of patients, respectively, but only 3%–5%
objective responses are encountered in neuroendocrine tumors.
As a consequence of the scintigraphic localization of
neuroendocrine tumors with radiolabeled somatostatin
analogues, therapeutic approaches with radiolabeled peptides
were developed. Peptide receptor radionuclide therapy (PRRT)
can deliver radiation doses to tumors, which are adequate to
achieve volume reduction [80]. The biological basis of PRRT is
the receptor-mediated internalization and intracellular
retention of the radiopeptide. Several clinical trials indicated
that PRRT with radiolabeled somatostatin analogues is among
the promising newly developed targeted tools in
neuroendocrine tumors [81].
Initial studies were performed with the administration of
high doses of the radiopeptide [In-111-DTPA0]-octreotide.
Objective responses were rare due to the short range of the
emission and therefore the short tissue penetration of the
particles (nanometers to micrometers). Among 40 patients
treated with cumulative doses of 20–160 GBq, one partial
remission, six minor remissions and 14 stabilization of disease
were reported. Mild hematological toxicity was observed, but
three cases of myelodysplastic syndrome (MDS) or leukemia
occurred in the patients treated with high activities (>100 GBq).
In another study in 27 patients with gastroenteropancreatic
neuroendocrine tumors, partial responses (more than 50%
reduction in size) occurred in two of 26 patients with
measurable disease. Renal insufficiency was reported in one
patient, although possibly not treatment related [82, 83].
The radiopeptide that has been most extensively studied is
[Y-90-DOTA0,Tyr3]-octreotide. Despite differences in clinical
phase I–II protocols from different centers, CR and partial
remission were observed in 10%–30% of patients, a rate
undoubtedly higher than that obtained with [In-111-DTPA0]-
octreotide. Moreover, survival of patients with metastatic
gastroenteropancreatic neuroendocrine tumors was longer after
[Y-90-DOTA0,Tyr3]-octreotide than [In-111-DTPA0]-
octreotide [84]. In a first report, 29 patients were treated with
a dose-escalating scheme consisting in four or more cycles of
Figure 2. Treatment of metastatic neuroblastoma with I-131-meta-
iodobenzylguanidine (mIBG). (A) I-131-mIBG scintigraphy before
treatment: extensive bone metastases. (B) I-131-mIBG scintigraphy after
two administrations of I-131-mIBG: no evidence of disease activity. Images
courtesy of A. McEwan and E. Postema, Cross Cancer Institute, Edmonton
AB, Canada.
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[Y-90-DOTA0,Tyr3]-octreotide with cumulative activities.
Twenty of these patients showed a disease stabilization, two had
partial remission, four minor remission and three progressed
[85]. In a subsequent study, 39 patients were treated with four
equal intravenous injections, for a total of 7.4 GBq/m2 of
[Y-90-DOTA0,Tyr3]-octreotide [86]. The objective response
rate was 23%, with CR in two patients, partial remission in
seven and stabilization in 27. Neuroendocrine pancreatic
tumors (13 patients) showed a higher objective response rate
(38%). A significant reduction of clinical symptoms was
recorded. Toxicity was generally mild and involved the kidney
and the bone marrow. However, renal insufficiency was
reported in five patients not receiving renal protection with
amino acids during the therapy, while severe hematological
toxicity occurred in those patients treated with high cumulative
activities.
Dosimetric and dose-escalating studies with
[90Y-DOTA0,Tyr3]-octreotide, with and without renal
protection showed no major acute reactions up to an
administered dose of 5.55 GBq per cycle [87]. Reversible grade
3 hematological toxicity was found in 43% of patients injected
with 5.18 GBq, which was defined as the MTD per cycle. None
of the patients developed acute or delayed kidney toxicity,
although follow-up was short. Partial and complete responses
(according to the WHO standard criteria) were reported in
28% of 87 patients with neuroendocrine tumors [87]. In
a multicenter phase 1 study, 60 patients received escalating
doses up to 14.8 GBq/m2 in four cycles or up to 9.3 GBq/m2 in
a single dose, without reaching the maximum tolerated single
dose. All patients received renal protection. Three patients had
DLT (liver toxicity, grade 4 thrombocytopenia and MDS). Four
of 54 patients (8%) treated with the highest dose had partial
response and seven patients (13%) had minor responses. The
median time to progression (TtP) in the 44 patients with SD,
minor or partial response was 30 months. Significant
biochemical and symptomatic responses in functioning tumors
were recorded [88, 89].
The newer somatostatin analogue [DOTA0,Tyr3]-octreotate
has a nine-fold higher affinity for the somatostatin receptor
subtype 2 compared with [DOTA0,Tyr3]octreotide [76]. In
a preliminary report, 35 patients with neuroendocrine
gastroenteropancreatic tumors were treated with escalating
doses of [Lu-177-DOTA0,Tyr3]-octreotate, resulting in
complete and partial responses in 38% of patients. No serious
side-effects were observed [90]. In a subsequent study, 131
patients with somatostatin receptor-positive tumors were
treated with up to a cumulative dose of 22.2–29.6 GBq of
[177Lu-DOTA0]-Tyr3-octeotate [91]. CR was observed in three
patients (2%), partial remission in 32 (26%), minor response in
24 (19%) and SD in 44 patients (35%), while 22 patients (18%)
progressed. Better responses were more frequent in case of high
uptake on baseline In-111-DTPA-octreotide scintigraphy and
in case of a limited number of liver metastases, while
progression was significantly more frequent in patients with
a low performance score and extensive disease at enrollment.
Median TtP was >36 months, comparing favorably to
chemotherapy. One patient developed renal insufficiency and
another patient developed hepatorenal syndrome. Severe
hematological toxicity occurred after <2% of the
administrations. In addition, [Lu-177-DOTA0]-Tyr3-octeotate
significantly improved the global health/quality of life and
various function and symptom scales in patients with
metastatic gastroenteropancreatic tumors [92].
Due to their marked radiosensitivity, the kidneys are the
critical organs in PRRT. Proximal tubular reabsorption of the
radiopeptide and the subsequent retention in the interstitium
results in renal irradiation. Given the high kidney retention of
radiopeptides, positively charged molecules, such as L-lysine
and/or L-arginine, are used to competitively inhibit the
proximal tubular reabsorption of the radiopeptide [93–96].
Despite kidney protection, renal function loss may become
clinically evident years after PRRT. A median decline in
creatinine clearance of 7.3% per year was reported in patients
treated with [Y-90-DOTA0,Tyr3]-octreotide and of 3.8% per
year in patients treated with [Lu-177-DOTA0,Tyr3]-octreotate.
Cumulative and per-cycle renal absorbed dose, age,
hypertension and diabetes are considered as contributing
factors to the decline of renal function after PRRT [97].
Besides renal toxicity, bone marrow involvement must be
considered although it appears not to be a principal dose-
limiting factor. Acute hematological toxicity grade 3 or 4 is not
uncommon, especially after [Y-90-DOTA0,Tyr3]-octreotide,
and the possibility of a mild, but progressive impoverishment
in bone marrow reserves has to be considered in repeated
cycles [96]. In addition, MDS or overt leukemia may develop
in patients receiving high bone marrow doses, especially in
those previously treated with alkylating agents [81].
The majority of the studies with [Y-90-DOTA0,Tyr3]-
octreotide are designed as phase I–II trials, thus not specifically
addressing efficacy. In addition, the rates of tumor remission
after [Y-90DOTA0,Tyr3]-octreotide treatment vary due to
different administered doses and dosage schemes, as well as
inhomogeneous patient characteristics, such as tumor type,
tumor load and liver involvement. Uniform pathology-oriented
phase II trials are required to assess the potential of peptide
receptor radionuclide therapy. [91]. Furthermore, to establish
which treatment scheme and which radiolabeled somatostatin
analogue or combination is optimal, randomized clinical trials
comparing different treatments are needed.
radionuclide therapy of liver tumors and
metastases
Liver tumors are a very important cause of morbidity and
mortality worldwide. For hepatocellular carcinoma (HCC),
resection or liver transplantation is the only curative treatment
available in the absence of extrahepatic metastases. However,
only 10%–15% of patients are eligible. Systemic chemotherapy
is generally no treatment option. In liver metastases of
adenocarcinoma, multimodality treatment is employed to
increase survival including surgery, systemic chemotherapy and
a wide variety of locoregional therapies, such as percutaneous
local ablative techniques (radiofrequency ablation, laser
coagulation, ethanol injection, cryotherapy, microwave
coagulation therapy) and transarterial regional techniques
(hepatic artery chemotherapy (HAC), transarterial
chemoembolization (TACE), transarterial radionuclide
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therapy, vena porta embolization, isolated hepatic
chemoperfusion). The big advantage of the locoregional
administration of agents is the much higher dose that can be
achieved in a single treatment.
Transarterial hepatic radionuclide therapy for HCC and liver
metastases dates back to the early 70s, when albumin colloids
labeled with Phosphorus-32 were first used. One line of
research has been the further development of such micrometer-
sized particles. When injected into a hepatic artery, such
particles preferentially lodge in the hypervasculature of liver
tumors (small arterioles, capillary sinusoids) and internally
irradiate the neighboring tumor tissue. By the virtue of the dual
blood supply, whereby the hepatic artery mainly perfuses
tumors while the normal parenchyma is mainly perfused via the
portal vein, a selective irradiation is achieved by the short
ranged beta-emitting isotopes attached to the particle. Today,
two of these products are commercially available, i.e. resin
microspheres (SIR-Spheres, Sirtex, Bonn, Germany) and glass
spheres (Theraspheres, Nordion, Fleurus, Belgium), both
labeled with Y-90. Another agent, lipiodol is a fatty acid
ester derivative of naturally occurring iodine-rich seed oil
which was previously widely used as computed tomography
contrast agent. Lipiodol labeled with I-131 is commercially
available (Lipiocis, Schering S.A., Berlin, Germany). This oily
substance is trapped in the tortuous tumor vessels but,
contrary to the spheres, is also taken up by tumor cells
by endocytosis. Figure 3 shows the accumulation of
I-131-lipiodol after intraarterial administration in a patient
with HCC.
Important advantages of radionuclide therapy for liver
tumors are its favorable toxicity profile and the feasibility of
combination with other therapies such as systemic
chemotherapy and limited liver resection without major
toxicity. Serious side-effects may occur in 5% (16/319) of
patients for I-131-lipiodol. Grade 3 and 4 toxicity occurs in
7% (23/336) of patients for SIR-spheres therapy. Furthermore,
treating the whole liver makes it more suitable for multiple
tumors as compared with local ablative strategies such as
radiofrequency ablation. Especially, microscopic subclinical
tumors are also effectively treated with this approach. The
feasibility of this has been demonstrated experimentally and
clinically [98].
I-131-lipiodol therapy has not been used in recent years
for liver metastases after early disappointing results [99]. This
may be related to its lower cellular uptake, its lower particle
radiation range and subsequently lower cross-fire radiation
effects in larger tumors. In HCC, the largest experience has
been with I-131-lipiodol as a single agent in palliative treatment
of inoperable cases. A collection of publications between 1986
and 2002 included 319 patients [100–103]. Overall, the average
radiological response rate of these was 28% (range 13%–100%)
and the average 1-year survival 31%. As HCC has a median
survival of only a few months, it appears that this treatment can
extend survival. However, the effect on survival remains
uncertain as only one small study randomized patients in
comparison with best medical support. [104]. This study
showed a significant difference in survival at 3 and 6 months
(71% versus 10% and 48% versus 0%), but there was no
survival at 12 months in both groups. However, this may be
related to the grave prognosis of portal thrombosis, as observed
by others [101]. One large prospective randomized study
comparing I-131-lipiodol with TACE observed similar response
rates and survival, but far better tolerability of I-131-lipiodol
(severe side-effects in 3% after I-131-lipiodol versus 29%
after TACE; six treatment-related deaths in the TACE group
within 15 days after treatment, but no mortality in the I-131-
lipiodol group) [105].
More recently, I-131-lipiodol therapy has been used as
adjuvant therapy after resection. A pilot study in 43
randomized patients reported 28.5% of recurrences in the
treated group versus 59% in the untreated control group with
a 3-year survival of 86% and 46%, respectively (P = 0.04) [98].
This study was criticized for a premature termination, but
subsequently it has been supported by nonrandomized,
retrospective studies [106, 107]. Low-range isotopes such as
I-131 may be more suitable for these patients with minimal
residual disease, as a larger fraction of the radiation energy will
Figure 3. (A) Pretherapeutic T1-weighted magnetic resonance imaging
(MRI) following gadolinium contrast in arterial phase showing a large,
inoperable hepatocellular carcinoma (HCC) tumor in the right liver lobe.
(B) High specific targeting is demonstrated on the computed tomography
(CT) scan of the liver performed 7 days after administration of 2.2 GBq
(60 mCi) I-131-lipiodol via selective canulation of the right hepatic artery.
In addition, very small, subclinical lesions are also targeted (arrows).
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be absorbed within the boundaries of the tumor as compared
with long-range isotopes such as Y-90 that may irradiate to
a larger fraction beyond such very small tumor cell clusters.
Two studies have piloted the neo-adjuvant use of I-131-
lipiodol before liver transplantation [108, 109]. Objective
radiological response in the first study was 50%. The second
study reported 1- and 3-year recurrence-free survival rates of
91% and 83%, respectively. These figures are very promising,
probably also because of the limited disease in these patients.
Larger, randomized studies are needed to assess its value. Given
the lack of liver donors, the most important role may be in
preventing patients to dropout because of tumor progression
while on the waiting list for transplantation.
A very interesting product development in lipiodol therapy
is the recent use of the isotope Re-188, which yields higher
dose rates and is readily available via a generator [110–112].
As no high-energy gamma rays are emitted, there is no need
for hospitalization and isolation for radiation protection.
SIR-spheres therapy (SIRT) has been used mainly to treat
liver metastases of CRC [113]. Recently, promising preliminary
results have also been reported for small groups of patients with
breast cancer metastases and HCC [114]. An early study by
Gray et al. [115] in patients with CRC liver metastases reported
a significant benefit in a phase III randomized trial in 74
patients in favor of HAC plus SIR-spheres, as compared with
HAC alone. Objective response was 44% versus 17%, median
TtP 15.9 versus 9.7 months and a trend for improved survival
(39% versus 29% after 2 years). Given this beneficial effect of
combined chemotherapy and radionuclide therapy, SIRT has
been studied in combination with standard systemic
chemotherapy. In the first study, 21 untreated patients were
randomized to 5-FU plus leucovorin alone or combined with
one cycle of SIRT. The results of the combined therapy were
impressively different: objective response 73% versus 0%,
median TtP 18.6 versus 3.6 months, without differences in
grade 3/4 toxicity and quality of life [116]. In further studies
by the same group, the combination of SIR-spheres with
irinotecan or FOLFOX showed similar preliminary results [117,
118]. In the former trial, TtP in the liver was 9.9 months (range
1.5–27+), anywhere 6.0 months (1.5–15+) with the dominant
site of progression being the lungs. Median survival in this
challenging patient group was 13.6 months (range 2.8–34+),
which compared favorably to phase III data from the literature
of 6.4–9.4 months.
Another option is the use of SIRT before or after resection
of hepatic tumors. Data from 226 tumors in 64 clinical trial
patients show a median tumor decrease of 60%, irrespective the
size, while >20% clinically disappear, the largest tumor 10 cm
in diameter. Downstaging to allow resection was evident in
20% of first-line patients. These seem favorable prerequisites
for further development of this indication. The future challenge
is the optimal integration of locoregional radionuclide therapy
into the increasing number of surgical, chemotherapeutic and
targeted treatment options.
conclusions
In recent years, significant developments in the application of
targeted radionuclide therapy have taken place, even in the
well-established I-131 treatment of thyroid cancer. New
treatment modalities, such as radiolabeled antibodies and
peptides, targeting specific antigens or receptors have been
introduced in the clinic. Local application of
radiopharmaceuticals in liver tumors may become an asset to
improve the still limited survival. The concept of combining
therapeutic radiopharmaceuticals with other treatment
modalities is more extensively explored. A gradual shift from
treating patients with bulky disease to patients with minimal
residual disease, for which radionuclide-based therapy is most
suitable, is continuously considered.
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